

DEXTENZA CODING OVERVIEW

Dextenza®
(dexamethasone ophthalmic insert) 0.4 mg
for intracanalicular use

Product Reimbursement

As of January 1, 2025, DEXTENZA has separate payment in the ASC and HOPD settings[†] due to meeting the criteria set forth in the non-opioid as a surgical supply provision by CMS[‡].

Product Code	Description
J1096 J-code*	Dexamethasone, lacrimal ophthalmic insert, 0.1mg

- 💡 When submitting a claim, enter a unit of **4** for the DEXTENZA HCPCS code (J1096). The HCPCS descriptor for DEXTENZA is 0.1mg.
- 💡💡 As of July 1, 2023, Providers must report **JZ modifiers**² on Medicare Part B claims for single use drugs.

Procedure Reimbursement

Procedure Code	Description
68841 CPT-code ^{3‡}	Insertion of drug-eluting implant including punctal dilation when performed, into lacrimal canaliculus, each

ICD[§]-10 Code Identification

- When billing for DEXTENZA (J1096), the diagnosis code (ICD-10)[§] should align with the primary procedure
- CMS's Medicare Coverage Database (MCD) Search is a resource that supports the identification of appropriate ICD-10 codes for the primary procedure.


<https://bit.ly/MCDsearch>




CMS's MCD Search

- Access link
- Type in Cataract or another ophthalmic surgery

- Pick the appropriate Medicare Administrative Contractor (MAC) and description
- On the next page, scroll down and select the appropriate ICD-10 codes



This may not be a complete list of ICD-10 codes, visit www.cms.gov/medicare/coding/medhpcpsgeninfo for all codes.



❗ Customers are responsible for determining the appropriate coding and submission of accurate claims.

National Drug Codes (NDC)

Product	Active Ingredient	Quantity	10-Digit NDC Number	11-Digit NDC Number
DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg	(dexamethasone USP)	1	70382-204-01	70382-0204-01
DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg	(dexamethasone USP)	10	70382-204-10	70382-0204-10

* A permanent code used to report non-orally administered drugs that cannot be self-administered. May be accompanied by a procedure-based CPT code.

† Medicare Advantage (Part C) and Commercial plans may or may not follow Medicare recommendations in making coverage decisions. Payment rates may vary per facility contracts.

‡ CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT), an alphanumeric coding system maintained by the American Medical Association to identify medical services and procedures provided by physicians and other healthcare professionals.

§ International Classifications of Diseases (ICD).

^{||} 10-Digit NDC code as assigned by FDA, certain payers accept the 10-digit format.

References: **1.** Federal Register. <https://www.federalregister.gov/documents/2024/11/27/2024-25521/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-and-ambulatory-surgical>. Accessed June 4, 2026. **2.** Centers for Medicare & Medicaid Services. <https://www.cms.gov/files/document/mm13056-new-jz-claims-modifier-certain-medicare-part-b-drugs.pdf>. Accessed June 4, 2026. **3.** MedicalBillingAndCoding.org. Intro to CPT Coding. <https://medicalbillingandcoding.org/intro-to-cpt/>. Accessed June 4, 2026.

Please see the Important Safety Information on next page and [click here](#) for full Prescribing Information.

Do You Have Reimbursement Questions?

Your dedicated resource and support team is available to help answer your questions and find comprehensive solutions with you throughout the reimbursement process—from benefits identification to appeals support.



Learn more at: www.dextenza.com/reimbursement-services

INDICATIONS

DEXTENZA is a corticosteroid indicated for:

- The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients
- The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older
 - Limitations of Use
The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

WARNINGS AND PRECAUTIONS

Intraocular Pressure Increase - Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Bacterial Infections - Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Viral Infections - Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections - Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Delayed Healing - Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Other Potential Corticosteroid Complications -

The initial prescription and renewal of the medication order of DEXTENZA should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

ADVERSE REACTIONS

Ocular Inflammation and Pain Following Ophthalmic Surgery

The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%), intraocular pressure increased (6%), visual acuity reduced (2%), cystoid macular edema (1%), corneal edema (1%), eye pain (1%), and conjunctival hyperemia (1%). The most common non-ocular adverse reaction was headache (1%).

Itching Associated with Allergic Conjunctivitis

The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: intraocular pressure increased (3%), lacrimation increased (1%), eye discharge (1%), and visual acuity reduced (1%). The most common non-ocular adverse reaction was headache (1%).

[Click here](#) for full Prescribing Information.

[Click here](#) to learn more at www.dextenza.com.

